Onco3R Therapeutics at the AACR-NCI-EORTC Meeting in Boston

Written By Evelien Micholt

We present three scientific posters showcasing the depth and innovation of our oncology pipeline, including our lead programs in FGFR3, SMARCA2, and p53. These presentations highlight our progress toward clinical candidate nomination and our commitment to developing best-in-class therapies with transformational potential. 

Evelien Micholt
Next

Onco3R Therapeutics reports first pre-clinical data from its best-in-class precision oncology portfolio at the 2025 AACR-NCI-EORTC symposium